RESEARCH NOTE

Open Access

Draft genome sequence of antimicrobial producing *Paenibacillus alvei* strain MP1 reveals putative novel antimicrobials

Magdalena Pajor^{1*}, Jonathan Sogin², Randy W. Worobo² and Piotr Szweda¹

Abstract

Objective: A *Paenibacillus* strain isolated in previous research exhibited antimicrobial activity against relevant human pathogens including *Staphylococcus aureus* and *Listeria monocytogenes*. In this study, the genome of the aforementioned strain, designated as MP1, was shotgun sequenced. The draft genome of strain MP1 was subject to multiple genomic analyses to taxonomically characterize it and identify the genes potentially responsible for its antimicrobial activity.

Results: Here we report the draft genome sequence of an antimicrobial producing *Paenibacillus* strain, MP1. Average Nucleotide Identity (ANI) analysis established strain MP1 as a new strain of the previously characterized *Paenibacillus alvei*. The genomic analysis identified several putative secondary metabolite clusters including seven Nonribosomal Peptide Synthetase clusters (NRPS) (> 10,000 nt), one bacteriocin or other unspecified Ribosomally Synthesized and Post-Translationally modified Peptide Product (RiPP), one lanthipeptide, and six hybrid clusters (NRPS-Type I Polyketide synthase (T1PKS) and NRPS-trans Amino Transferase Polyketide Synthase (AT-PKS)).

Keywords: Paenibacillus alvei, Whole genome sequencing, Antimicrobial-producing strain, NRPS

Introduction

Paenibacillus spp. produce a variety of peptide and nonpeptide-containing antimicrobial compounds. These compounds include hydrolytic enzymes, lantibiotics, polymyxins, paenibacterin, various organic molecules, and others [1]. Of these compounds, antimicrobial peptides are a promising group to target for the discovery of novel metabolites. These peptides are broadly classified based on their synthesis mechanism: ribosomallysynthesized bacteriocins and nonribosomally synthesized peptides (NRPs). Whereas bacteriocins are ribosomallysynthesized and post-translationally modified, NRPs are produced by large enzymes called nonribosomal peptide

*Correspondence: magdalena.pajor@pg.edu.pl

¹ Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza Street 11/12, 80-233 Gdańsk, Poland synthetases (NRPSs). NRPSs catalyze the incorporation and elongation of growing peptide chains without an RNA template. Regiospecific and stereospecific reactions catalyzed by NRPSs allow for the incorporation of noncanonical amino acids into these peptides, which contributes to the structural diversity of NRPs [2]. However, the discovery of NRPs is limited to genetic screens and genomic-based prediction of NRPs based on the structure of active sites in NRPSs. Therefore, many NRPs may be novel and yet to be discovered.

Although there is increasing interest in *Paenibacillus* spp. for the discovery of novel antimicrobials, the genomic information of these bacteria remains insufficient [3]. Previously, a *Paenibacillus* strain isolated from buckwheat honey [4] was identified as a producer of antimicrobial compound(s) with activity against both Gram-positive and Gram-negative pathogens, including *S. aureus* and *L. monocytogenes*. The goal of this study



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Full list of author information is available at the end of the article

was to conduct whole-genome sequencing of this strain, hereafter designated MP1, to taxonomically characterize it and identify genes possibly responsible for the production of the compound(s) that yield strain MP1 its antimicrobial activity.

Main text

Methods

Strain MP1 was maintained at -80 °C in 15% (vol/vol) glycerol Luria-Bertani medium (Becton-Dickinson, Franklin Lakes, NJ). Prior to extraction, strain MP1 was streaked and grown on Luria-Bertani agar. Genomic DNA was isolated from a culture of strain MP1 grown by inoculating 9 mL Luria-Bertani medium with a single colony and incubating at 37 °C for 18 h with continuous shaking at 200 rpm. DNA was extracted from 1.8 mL culture using the QiaAMP DNA Minikit (Qiagen, Germantown, MD) following a slightly modified protocol. In brief, cells were pelleted and subjected to lysozyme (20 mg/mL) treatment (Millipore Sigma, St. Lois, MO) at 37 °C for 60 min; DNA was extracted from this lysate using the QiaAMP DNA Minikit following manufacturer instructions for RNA-free genomic DNA using RNase A (Qiagen, Germantown, MD). Following extraction, DNA was spectrophotometrically quality checked using a NanoDrop (Thermo Fisher, Waltham, MA) to ensure the 260/280 and 260/230 nm absorbance ratios were greater than 1.8 and 2.0 respectively. Library preparation, quality control, and sequencing were conducted by the Cornell University Veterinary Molecular Diagnostics Laboratory utilizing the Nextera XT DNA library preparation and indexing kits (Illumina, San Diego, CA) and an Illumina MiSeq (Illumina, San Diego, CA) to obtain 2×250 bp paired-end reads; this yielded 3,467,242 raw reads (866 Mb).

Raw reads were trimmed and paired using Trimmomatic (v0.39) [5] with the parameters: LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:26. Trimmed and paired reads were first quality checked using FastQC (v0.11.8) [6] to ensure normal results for 'per base sequence quality,' per base N content,' sequence duplication levels' and 'adapter content,' and then de novo assembled into scaffolds using SPAdes (v3.13.1) [7–9] with the parameters: -k 33,55,77,99,127 -careful. Following assembly, scaffolds less than 500 bp were removed. QUAST (v4.0) [10] was used to obtain basic assembly statistics (e.g. # scaffolds, N_{50} , G+C content), and BBmap (v37.50) [11] and Samtools (v1.9) [12] were used to determine average sequencing coverage as previously described [13].

The species identification of strain MP1 was determined by ANI analysis of strain MP1's genome versus the whole genomes of all available *Paenibacillus* type strains deposited in the National Center for Biotechnology Information (NCBI) assembly database. Following this, all-v-all ANI analysis was conducted among all strains with whole genomes deposited in the NCBI assembly database for the species of the closest related type strain. ANI analysis was conducted via the OrthoANI method using OAT (v1.40) [14] with BLAST + (v2.9.0) [15]. The species and strain names for both sets of comparisons can be found in Supplementary Data - Data 1 and Data 2. Hierarchical cluster analysis was conducted in R (v3.5.3) [16] via the complete-linkage method on dissimilarity values between strains for the species of the closest related type strain, computed as $1 - \frac{ANI\%}{100}$, to determine relatedness. Cluster analysis was visualized using R.

Genome annotation was conducted by the NCBI using the Prokaryotic Genome Annotation Pipeline (PGAP) [17, 18]. Because it was determined that strain MP1 produces antimicrobial compounds, the PGAP annotated genome was further analyzed using the AntiSMASH webserver (v5.1.0) [19] to identify putative secondary metabolite clusters and compare synteny of those clusters to related clusters in other genomes. Genes of interest identified by AntiSMASH were translated and compared to related proteins in the non-redundant protein sequences database using the NCBI BLASTp suite with default settings [20]. The genome of strain MP1 was compared to the type strain of the identified species using Mauve (v20150226) [21, 22] with progressive alignment and seed-families options, and the webserver Phaster [23, 24].

Results

The resulting assembly of strain MP1 contained 116 scaffolds with an N_{50} value of 129,056 bp, 46.11% G+C content, and 6,511,289 bp; average sequencing coverage was 106.03 × (Additional file 1: Summary Quast Table). The draft genome of strain MP1 (annotated via PGAP) encodes 5915 genes; 5626 are coding sequences, 198 are pseudogenes, and 91 are functional or regulatory RNAs. Of the functional or regulatory RNAs, 71 are tRNAs, 5 are complete rRNAs (5–5S), 11 are partial rRNAs (1–5S, 3–16S, and 7–23S), and 4 are ncRNAs; the genome also contains 3 CRISPR arrays.

ANI analysis showed strain MP1 was most closely related to type strain *P. alvei* DSM 29 (97.68%, refseq accession GCF_000293805.1) (Additional file 2). When compared to other strains within the species *P. alvei*, MP1 was more distantly related: B-LR (84.89%, GCF_900519125.1), TS-15 (84.78%, GCF_000442555.1), and A6-6i-x (84.60%, GCF_000442535.1) (Additional file 3). However, these values are higher than the ANI values between strain MP1 and other *Paenibacillus* type strains (median = 67.78%, 1st quartile = 67.51%, 3rd


quartile = 67.97%, n = 124). Hierarchical cluster analysis revealed two distinct clusters above 95% ANI; one cluster contained strains MP1 and DSM 29, and the other contained strains B-LR, TS-15, and A6-6i-x (Fig. 1). ANI values were computed via the orthoANI algorithm and ANI distances were calculated as 1 - ANI(%)/100. Hierarchical cluster analysis was computed via the complete-linkage method. Numbers in parentheses correspond to the NCBI RefSeq accession number for the assembly used in the analysis. The vertical red line corresponds to a 95% ANI threshold commonly used for species designations.


When comparing the genome of strain MP1 to the genome of type strain *P. alvei* DSM 29 (including 4 plasmids), subtle differences were revealed. Strain MP1 contained 626 less genes than the whole genome of type strain DSM 29 (6,541 genes). When visualized using Mauve, it became clear that divergent regions were related to the presence of mobile genetic elements (plasmids, prophage, and transposons) within each genome, specifically plasmids and prophage. This was confirmed when the individual genomes were analyzed using Phaster. The results from Phaster indicate a difference of 594 genes attributed to the presence of 13 prophage regions in strain MP1 (total = 377 genes) vs 20 in type strain DSM 29 (total = 971) (Additional files 4 and 5).

AntiSMASH analysis of the PGAP annotated MP1 genome predicted the presence of several putative

secondary metabolite clusters including seven NRPS clusters (operons > 10,000 nt), one bacteriocin, one lanthipeptide, four hybrid NRPS clusters containing NRPSs and polyketide synthetases (type I or *trans*-acyltransferase), one hybrid cluster containing a lasso peptide and NRPSs, and one hybrid cluster containing a sactipeptide and resorcinol. Notably, strain MP1 contained one large operon with five putative NRPS genes spanning 71,579 nt with no similarity to genes involved in the biosynthesis of other known NRPs; type strain DSM 29 contained a similar cluster that displayed synteny with strain MP1 (Fig. 2d). In addition, other clusters encoding for a bacteriocin, sactipeptide, and lasso peptide were identified with no similarity to known antimicrobial producing gene clusters.

Three clusters were identified with 100% similarity to known NRP synthesis pathways; each of these clusters showed synteny with clusters identified in type strain DSM 29 (Fig. 2a-c). One hybrid gene cluster contained NRPS genes showing similarity to genes involved in the synthesis of polymyxin B. When the translated sequences of these genes were compared to related proteins using BLASTp, they displayed high similarity to proteins involved in the synthesis of variant forms of polymyxin B (1 and 2) produced by a strain of *P. polymyxa* [25]: PmxA (89.15%, AEZ51516.1), PmxB (96.28%, AEZ51517.1), PmxC (95.89%, AEZ51518.1), (98.61%, PmxD





AEZ51519.1), PmxE (95.41%, AEZ51520.1). Another hybrid cluster contained NRPS genes showing similarity to genes involved in the synthesis of paenibacterin. When the translated sequences of these genes were compared to related proteins using BLASTp, they displayed similarity to proteins involved in the synthesis of paenibacterin produced by a strain of *P. thiaminolyticus* [26]: PbtA (67.45%, AGM16412.1), PbtB (67.70%, AGM16413.1), PbtC (60.12%, AGM16414.1), PbtD (72.87%, AGM16415.1), and PbtE (70.92%, AGM16416.1). Finally, a NRPS cluster contained NRPS genes showing similarity to genes involved in the synthesis of paenibactin. When the translated sequences of these genes were compared to related proteins using BLASTp, they displayed similarity to proteins involved in the synthesis of paenibactin produced by a strain of *P. elgii* [27]: PaeG (59.64%, AEI70240.1), PaeA (75.00%, AEI70241.1), PaeC (58.17%, AEI70242.1), PaeE (77.09%, AEI70243.1), PaeB (66.56%, AEI70244.1), and PaeF (67.78%, AEI70245.1).

Discussion

The ANI value between MP1 and type strain *P. alvei* DSM 29 indicates that strain MP1 is a new strain within the species *Paenibacillus alvei* when considering the 95% threshold suggested by others [28, 29]. However, the ANI values between strain MP1 and other *P. alvei* strains, and the hierarchical cluster analysis, suggests that at present, *P. alvei* is a fragmented species. ANI values between type strain DSM 29 and the others were lower than 95%, which indicates those strains were originally misclassified

and/or represent a novel species of *Paenibacillus*. Strains MP1 and DSM 29 both originated from honey or beerelated sources [4, 30], whereas the others did not [3, 31]; the introduction of a common ancestor to bees could have led to niche specialization that caused speciation.

The difference in the number of genes between strains MP1 and DSM 29 is almost completely attributed to differences in mobile genetic element composition, namely phage and plasmids. Type strain DSM 29 contains 4 plasmids, two which contain putative prophage; the method used to assemble the genome of strain MP1 does not attempt to identify plasmids. However, when analyzed for the presence of prophage, it became clear that almost the entire difference in the number of genes within each of the assemblies was due to differences in the composition of prophage. The remaining difference is likely due to the presence of plasmid associated maintenance genes that were not identified during prophage analysis. Varying mobile genetic element composition is reasonable to expect given the geographic origin of each isolate (MP1-Poland, DSM 29-United Kingdom); the population of phage in communities is dynamic, and geographic origin likely affected the composition of microbial communities, including phage, each isolate was exposed to. Nonetheless, due to the high ANI value between MP1 and DSM 29, strain MP1 is a new representative of the P. alvei species.

AntiSMASH analysis of the PGAP annotated MP1 genome confirmed its potential to produce a variety of nonribosomal peptides and polyketides. Some of the

identified clusters were related to previously known compounds including polymyxin, paenibacterin, and paenibactin; others were not—such as the lasso peptide cluster. The most recent results support that the structure of paenibacterin as a cyclic lipodepsipeptide antibiotic might be useful for creating new antibiotics via synthetic routes [32], which is necessary as antimicrobial resistance arise and requires the development of novel antimicrobial agents. Furthermore, lasso peptides constitute a group of relatively new, non-toxic natural compounds with antimicrobial activity, however, their highly stable structure requires further molecular modification for potential medical applications [33]. Paeninodin synthesized by P. dendritiformis C454 was reported in 2016 as the novel lasso peptide tailored by a new class of kinases [34]. The potential use of these antimicrobials indicates that further investigation of antimicrobials produced by members of the genus Paenibacillus, including strain MP1, could lead to the discovery of medically relevant (or otherwise) compounds for use against pathogenic organisms.

Finally, this study demonstrates several antimicrobial compounds are yet to be characterized and highlights the necessity to experimentally verify the function of synthesis genes. Such efforts will result in a better understanding of the structure and synthesis of antimicrobial compounds and will lead to better genome-based predictions in the future.

Limitations

The acknowledged analysis is based on the draft genome of strain MP1. Therefore, regions of the complete genome may be duplicated or missing from the assembly.

Supplementary information

Supplementary information accompanies this paper at https://doi. org/10.1186/s13104-020-05124-z.

Ad	ditional	file	1: Data	1.	The	QUAST	Sumi	mary	tab	le
----	----------	------	---------	----	-----	-------	------	------	-----	----

Additional file 2: Data 2. OrthoAni_Paenibacillus_type_strains.

Additional file 3: Data 3. OrthoAni_Paenibacillus_alvei.

Additional file 4: Data 4. DSM29_prophage_supplement.

Additional file 5: Data 5. MP1_prophage_supplement.

Abbreviations

ANI: Average Nucleotide Identity; NRPS: Nonribosomal Peptide Synthetase clusters; NRPSs: Nonribosomal Peptide Synthetases; RiPP: Ribosomally Synthesized and Post-translationally modified Peptide Product; T1PKS: Type I Polyketide synthase; AT-PKS: Amino Transferase Polyketide Synthase; NCBI: The National Center for Biotechnology Information; PGAP: Prokaryotic Genome Annotation Pipeline; SRA: Sequence Read Archive; Nt: Nucleotide.

Acknowledgements

Not applicable.

Authors' contributions

MP—experimental design and DNA extraction; processing and interpretation of experimental data; writing the manuscript. JS—processing and interpretation of experimental data; writing the manuscript. RWW—Revising the manuscript, financial support of analysis-S1077 Multi-state grant. PS—Revising the manuscript, partial financial support of Grant No. 2015/18/E/NZ6/00700. All authors read and approved the final manuscript.

Funding

The research was financed by the [Grant No 2015/18/E/NZ6/00700] from the "National Science Centre, Poland" and by the S1077 Multi-state grant (Cornell University). The funding bodies played no role in the design of the study, or the collection, analysis, and interpretation of data, or the writing of the manuscript.

Availability of data and materials

This Whole Genome Shotgun project has been deposited at DDBJ/ENA/Gen-Bank under the accession WSQB0000000. The version described in this paper is version WSQB01000000. The *Palvei MP1* strain is available upon request from R.W. Worobo or P. Szweda.

Ethics approval and consent to participate

Not applicable.

Consent for publications

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza Street 11/12, 80-233 Gdańsk, Poland. ² Department of Food Science, Cornell University, Stocking Hall, Ithaca, NY 14853-7201, USA.

Received: 16 February 2020 Accepted: 4 June 2020 Published online: 09 June 2020

References

- Grady EN, MacDonald J, Liu L, Richman A, Yuan Z-C. Current knowledge and perspectives of Paenibacillus: a review. Microb Cell Fact. 2016;15:203.
- Strieker M, Tanovic A, Marahiel M. Nonribosomal peptide synthetases: structures and dynamics. Curr Opin Struct Biol. 2010;20:234–40.
- Luo Y, Wang C, Allard S, Strain E, Allard MW, Brown EW, et al. Draft genome sequences of *Paenibacillus alvei* A6-6i and TS-15. Genome Announc. 2013;1:e00673. https://doi.org/10.1128/genomeA.00673-13.
- Pajor M, Worobo RW, Milewski S, Szweda P. The antimicrobial potential of bacteria isolated from honey samples produced in the Apiaries located in Pomeranian Voivodeship in Northern Poland. Int J Environ Res Public Health. 2018;15:2002.
- Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.
- 6. FASQC. https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77. https://doi. org/10.1089/cmb.2012.0021.
- Vasilinetc I, Prjibelski AD, Gurevich A, Korobeynikov A, Pevzner PA. Assembling short reads from jumping libraries with large insert sizes. Bioinformatics. 2015;31:3262–8.
- Prjibelski AD, Vasilinetc I, Bankevich A, Gurevich A, Krivosheeva T, Nurk S, et al. ExSPAnder: a universal repeat resolver for DNA fragment assembly. Bioinformatics. 2014;30:i293–301.
- Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29:1072–5. https://doi. org/10.1093/bioinformatics/btt086.

- Bushnell B. BBMap: A Fast, Accurate, Splice-Aware Aligner. United States; 2014. https://www.osti.gov/servlets/purl/1241166.
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
- Carroll LM, Wiedmann M, den Bakker H, Siler J, Warchocki S, Kent D, et al. Whole-genome sequencing of drug-resistant *Salmonella enterica* isolates from dairy cattle and humans in New York and Washington States reveals source and geographic associations. Appl Environ Microbiol. 2017. https ://doi.org/10.1128/aem.00140-17.
- Lee I, Ouk Kim Y, Park S-C, Chun J. OrthoANI: an improved algorithm and software for calculating average nucleotide identity. Int J Syst Evol Microbiol. 2016;66:1100–3.
- Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+ : architecture and applications. BMC Bioinformatics. 2009;10:421. https://doi.org/10.1186/1471-2105-10-421.
- R Core Team (2019). Methodology Reference Indicator codes: CSI 019, WAT 002. 2019. http://www.r-project.org/index.html.
- Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016;44:6614–24.
- Haft DH, DiCuccio M, Badretdin A, Brover V, Chetvernin V, O'Neill K, et al. RefSeq: an update on prokaryotic genome annotation and curation. Nucleic Acids Res. 2018;46:D851–60.
- Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee SY, et al. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic Acids Res. 2019;47:W81–7. https://doi.org/10.1093/nar/gkz310.
- 20. Madden T, Tatusov R, Zhang J. [9] Applications of network BLAST server. Methods Enzymol. 1996;266:131–41.
- Darling ACE, Mau B, Blattner FR, Perna NT. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res. 2004;14:1394–403. http://genome.cshlp.org/content/14/7/1394.abstract.
- Darling AE, Mau B, Perna NT. ProgressiveMauve: multiple genome alignment with gene gain. Loss and Rearrangement. PLoS ONE. 2010;5:e11147. https://doi.org/10.1371/journal.pone.0011147.
- Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, et al. PHASTER: a better, faster version of the PHAST phage search tool. Nucleic Acids Res. 2016;44:W16–21. https://doi.org/10.1093/nar/gkw387.
- Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. PHAST: a fast phage search tool. Nucleic Acids Res. 2011;39(2):347–52. https://doi. org/10.1093/nar/gkr485.

- Huang E, Guo Y, Yousef AE. Biosynthesis of the new broad-spectrum lipopeptide antibiotic paenibacterin in Paenibacillus thiaminolyticus OSY-SE. Res Microbiol. 2014;165:243–51. https://doi.org/10.1016/j.resmi c.2014.02.002.
- Wen Y, Wu X, Teng Y, Qian C, Zhan Z, Zhao Y, et al. Identification and analysis of the gene cluster involved in biosynthesis of paenibactin, a catecholate siderophore produced by *Paenibacillus elgii* B69. Environ Microbiol. 2011;13:2726–37. https://doi.org/10.1111/j.1462-2920.2011.02542.x.
- Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. Nat Commun. 2018;9:5114. https://doi.org/10.1038/ s41467-018-07641-9.
- Goris J, Konstantinidis KT, Klappenbach JA, Coenye T, Vandamme P, Tiedje JM. DNA-DNA hybridization values and their relationship to whole-genome sequence similarities. Int J Syst Evol Microbiol. 2007;57(Pt 1):81–91.
- Djukic M, Becker D, Poehlein A, Voget S, Daniel R. Genome sequence of Paenibacillus alvei DSM 29, a secondary invader during European foulbrood outbreaks. J Bacteriol. 2012;194:6365.
- Salsano C, Didelot S, Tambadou F, Caradec T, Sopéna V, Barthélémy C, et al. Complete genome sequence of the polymyxin E (Colistin)producing Paenibacillus sp. Strain B-LR. Microbiol Resour Announc. 2018;7:e01013–8. https://doi.org/10.1128/MRA.01013-18.
- 32. Noden M, Moreira R, Huang E, Yousef A, Palmer M, Taylor SD. Total synthesis of Paenibacterin and its analogues. J Org Chem. 2019;84:5339–47. https://doi.org/10.1021/acs.joc.9b00364.
- Zhao N, Pan Y, Cheng Z, et al. Lasso peptide, a highly stable structure and designable multifunctional backbone. Amino Acids. 2016;48:1347–56.
- Zhu S, Hegemann JD, Fage CD, Zimmermann M, Xie X, Linne U, et al. Insights into the unique phosphorylation of the Lasso Peptide Paeninodin. J Biol Chem. 2016;291:13662–78.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

